Juan Fu

Juan Fu

Auto-generated profile, based on publicly available information

Juan Fu

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MWMarc Wehrli
Marc Wehrli
SGSamantha Guinn
Samantha Guinn
FBFilippo Birocchi
Filippo Birocchi
AKAdam Kuo
Adam Kuo
YSYi Sun
Yi Sun
MMMarcela V. Maus
Marcela V. Maus
Purpose: Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is characterized by a thick stroma generated by cancer-associated fibroblasts (CAF), which may contribute to the limited efficacy of mesothelin-directed CAR T cells in early-phase clinical trials. To provide a more favorable TME for CAR T cells to target pancreatic ductal adenocarcinoma (PDAC), we generated T cells with an antimesothelin CAR and a secreted T-cell–engaging molecule (TEAM) that targets CAF through fibroblast activation protein (FAP) and engages T cells through CD3 (termed mesoFAP CAR-TEAM cells). Experimental Design: Using a suite of in vitro, in vivo, and ex vivo patient-derived models containing cancer cells and CAF, we examined the ability of mesoFAP CAR-TEAM cells to target PDAC cells and CAF within the TME. We developed and used patient-derived ex vivo models, including patient-derived organoids with patient-matched CAF and patient-derived organotypic tumor spheroids. Results: We demonstrated specific and significant binding of the TEAM to its respective antigens (CD3 and FAP) when released from mesothelin-targeting CAR T cells, leading to T-cell activation and cytotoxicity of the target cell. MesoFAP CAR-TEAM cells were superior in eliminating PDAC and CAF compared with T cells engineered to target either antigen alone in our ex vivo patient-derived models and in mouse models of PDAC with primary or metastatic liver tumors. Conclusions: CAR-TEAM cells enable modification of tumor stroma, leading to increased elimination of PDAC tumors. This approach represents a promising treatment option for pancreatic cancer.

11 April 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JWJianxin Wang
Jianxin Wang
MSMay Tun Saung
May Tun Saung
KLKeyu Li
Keyu Li
JFJuan Fu
Juan Fu
KFKenji Fujiwara
Kenji Fujiwara
Lei ZhengLei Zheng
Lei Zheng
The resistance of pancreatic ductal adenocarcinoma (PDAC) to immune checkpoint inhibitors (ICIs) is attributed to the immune-quiescent and -suppressive tumor microenvironment (TME). We recently found that CCR2 and CCR5 were induced in PDAC following treatment with anti–PD-1 antibody (αPD-1); thus, we examined PDAC vaccine or radiation therapy (RT) as T cell priming mechanisms together with BMS-687681, a dual antagonist of CCR2 and CCR5 (CCR2/5i), in combination with αPD-1 as new treatment strategies. Using PDAC mouse models, we demonstrated that RT followed by αPD-1 and prolonged treatment with CCR2/5i conferred better antitumor efficacy than other combination treatments tested. The combination of RT + αPD-1 + CCR2/5i enhanced intratumoral effector and memory T cell infiltration but suppressed regulatory T cell, M2-like tumor–associated macrophage, and myeloid-derived suppressive cell infiltration. RNA sequencing showed that CCR2/5i partially inhibited RT-induced TLR2/4 and RAGE signaling, leading to decreased expression of immunosuppressive cytokines including CCL2/CCL5, but increased expression of effector T cell chemokines such as CCL17/CCL22. This study thus supports the clinical development of CCR2/5i in combination with RT and ICIs for PDAC treatment.

1 May 2024
Verified
Other
Open access
PDF file
MWMarc Wehrli
Marc Wehrli
SGSamantha Guinn
Samantha Guinn
FBFilippo Birocchi
Filippo Birocchi
AKAdam Kuo
Adam Kuo
YSYi Sun
Yi Sun
MMMarcela V. Maus
Marcela V. Maus
Supplementary Figure S7. Superior anti-tumor effect of meso^FAP compared to the combination of meso-CAR and FAP-CAR or meso^CD19.

1 May 2024
Verified
Other
Open access
PDF file
MWMarc Wehrli
Marc Wehrli
SGSamantha Guinn
Samantha Guinn
FBFilippo Birocchi
Filippo Birocchi
AKAdam Kuo
Adam Kuo
YSYi Sun
Yi Sun
MMMarcela V. Maus
Marcela V. Maus
Supplementary Figure S6. Human CAF-1 cells do not expand in vivo in NSG mice in the presence or absence of AsPC-1 or PDX1294 cells.

1 May 2024
Verified
Other
Open access
MWMarc Wehrli
Marc Wehrli
SGSamantha Guinn
Samantha Guinn
FBFilippo Birocchi
Filippo Birocchi
AKAdam Kuo
Adam Kuo
YSYi Sun
Yi Sun
MMMarcela V. Maus
Marcela V. Maus
Supplementary Video S12. UTD T cells not on target

1 May 2024
Verified
Other
Open access
PDF file
MWMarc Wehrli
Marc Wehrli
SGSamantha Guinn
Samantha Guinn
FBFilippo Birocchi
Filippo Birocchi
AKAdam Kuo
Adam Kuo
YSYi Sun
Yi Sun
MMMarcela V. Maus
Marcela V. Maus
Supplementary Figure S5. Intratumoral multiplex RNA-ISH IF imaging and analysis of CAR-TEAM treated mice.